Results 21 to 30 of about 452 (85)
Aspects of anticoagulant therapy in venous thromboembolism, pulmonary embolism. Focus on elderly patients [PDF]
, 2022 The prevalence and mortality due to venous thromboembolism (VTE) occupies a leading position among the population throughout the world. The incidence and severity of VTE increases the older the patient.
D. V. Puzenko, M. V. Romanova
core +2 more sources
NEW ORAL ANTICOAGULANTS IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION AND CHRONIC KIDNEY DISEASE
Атеротромбоз, 2015 About 10% of the adult population is diagnosed with chronic kidney disease (CKD), and its presence is associated with a high risk of developing cardiovascular diseases including ventricular fibrillation (VF).
E. P. Panchenko
doaj +1 more source
NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETY
Рациональная фармакотерапия в кардиологии, 2015 Comparative analysis of oral anticoagulants (vitamin K antagonists and new drugs, including dabigatran, rivaroxaban and apixaban) is presented from the standpoint of safety.
D. A. Napalkov, A. A. Sokolova
doaj +1 more source
СТРАТЕГИЯ ВЕДЕНИЯ ПАЦИЕНТА С ФИБРИЛЛЯЦИЕЙ ПРЕДСЕРДИЙ С ЦЕЛЬЮ СНИЖЕНИЯ РИСКА ТРОМБОЭМБОЛИЧЕСКИХ ОСЛОЖНЕНИЙ [PDF]
, 2019 Over the past 20 years, the burden of atrial fibrillation (AF) has increased. AF is associated with increased risk of death, ischemic stroke and disability, hospitalization rates, and reduced quality of life.
E. Filippov V. +3 more
core +4 more sources
Рациональная фармакотерапия в кардиологии, 2015 For prevention of thromboembolic events in patients with non-valvular atrial fibrillation (NVAF) the following types of antithrombotic therapy are used: anticoagulant therapy with vitamin K antagonists (warfarin), antiplatelet therapy (acetylsalicylic ...
A. V. Rudakova
doaj +1 more source
Антитромботическая терапия при фибрилляции предсердий: новые пероральные антикоагулянты
Медицинский совет, 2014 Хорошо известно, что самыми частыми и грозными осложнениями фибрилляции предсердий (ФП) являются системные тромбоэмболии (ТЭ) и в еще большей степени ишемические инсульты (ИИ). Известно также, что основным источником ТЭ являются тромбы в левом предсердии
doaj +1 more source
Effect of ABCB1 Gene Carriage and Drug-Drug Interactions on Apixaban and Rivaroxaban Pharmacokinetics and Clinical Outcomes in Patients with Atrial Fibrillation and Deep Vein Thrombosis [PDF]
, 2023 Aim. To investigate the effect of ABCB1 gene carriage and interdrug interactions on apixaban pharmacokinetics and clinical outcomes in patients with atrial fibrillation and deep vein thrombosis.Material and methods.
A. A. Kachanova +9 more
core +2 more sources
Рациональная фармакотерапия в кардиологии, 2015 Aim. Pharmacoeconomic analysis of apixaban use compared to conventional therapy in patients with venous thromboembolism (VTE).Material and methods. Economic evaluation was performed from a position of the health care system.
O. V. Shatalova
doaj +1 more source
Атеротромбоз, 2016 В статье обсуждаются современные представления о подходах к антитромботической терапии после острого коронарного синдрома (ее длительность, сочетание препаратов, особенности в различных клинических ситуациях).
doaj +1 more source
Апиксабан – от рекомендаций к повседневной практике
, 2016 The articles deals with the analysis of clinical situations in patients with atrial fibrillations in the aspect of choice of the anticoagulant therapy with apixaban use in relation with the recent (2015) recommendations of the European Heart Rhythm ...
Л. Н. Елисеева +3 more
semanticscholar +1 more source